Group items tagged

This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). Also listed under U01.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies are outside the scope of this FOA.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies are outside the scope of this FOA.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies is outside the scope of this FOA.

Reissue of RFA-NS-18-032. The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II) This greater funding stability will provide eligible investigators at nearly all career stages increased freedom and flexibility, allowing them to be more adventurous in their research, take greater risks, embark upon research that breaks new ground, undertake research projects that require a longer timeframe, and/or extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission

NAF research grants are for new and innovative studies that are relevant to the cause, pathogenesis or treatment of the hereditary or sporadic ataxias. Research grants are offered primarily as "seed monies" to assist investigators in the early or pilot phase of their studies and as additional support for ongoing investigations on demonstration of need. It is hoped that these studies will be further developed to attract future funding from other sources. Grants are awarded for one year only. The funds granted will be up to $50,000 per award. Applicants for seed-money grants must be faculty members.

This Funding Opportunity Announcement (FOA) intends to accelerate the use of scalable technologies and tools to enhance brain cell census research, including the development of technology platforms and/or resources and the generation of spatiotemporal cell census data and/or resources. Applications are expected to address limitations and gaps of existing technologies/tools as a benchmark against which the improvements or competitive advantages of the proposed ones will be measured. The improvements include throughput, sensitivity, selectivity, scalability, spatiotemporal resolution and reproducibility in cell atlas analyses. The projects funded under this FOA will align with the overarching goals of the BRAIN Initiative Cell Census Network (BICCN) and are expected to enable the generation of a large amount of cell census data using the proposed technologies or via collaboration with the BICCN.

The Science Undergraduate Research Grant (SURG) Program is designed for faculty researchers and their students to gain access to cutting edge life science technology and incorporate it into the classroom. The SURG program's goal is to increase inquiry-based learning by providing the tools necessary to accelerate both students' and instructors' research and improve the quality of their science curriculum. LI-COR Biosciences is awarding a limited number of matching fund grants (value up to $18,400) to eligible academic institutions within the United States and Puerto Rico to be used toward the purchase of a LI-COR Odyssey® Fc Imaging System including the instrument, software, and reagents. LI-COR SURG grants are a 40% match from LI-COR with the institution providing 60%.

This funding opportunity announcement (FOA) invites applications for basic research to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in both normal aging and Alzheimer's disease (AD). Research is sought that will characterize the extent to which basic behavioral and neural processes involved in decision-making are differentially impacted in normal aging and AD, investigate the influence of social factors on decision-making, and investigate the decision-making factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse. The FOA also invites applications to apply basic research on the processes involved in decision-making to the design of decision-supportive interventions for midlife and older adults with and without AD. Specific opportunities include the development of decision-supportive interventions to leverage cognitive, emotional and motivational strengths of these populations; tools to assess decisional capacity; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wells, etc.).

This funding opportunity announcement (FOA) invites applications for basic research to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in both normal aging and Alzheimer's disease (AD). Research is sought that will characterize the extent to which basic behavioral and neural processes involved in decision-making are differentially impacted in normal aging and AD, investigate the influence of social factors on decision-making, and investigate the decision-making factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse. The FOA also invites applications to apply basic research on the processes involved in decision-making to the design of decision-supportive interventions for midlife and older adults with and without AD. Specific opportunities include the development of decision-supportive interventions to leverage cognitive, emotional and motivational strengths of these populations; tools to assess decisional capacity; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wells, etc.).

The ADDF-Harrington Scholar Program is a collaboration between the Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. The goal of developing new therapies will be achieved by providing award recipients with both research funding and committed project support by a team of pharmaceutical industry experts. Proposals should show potential to advance discovery into meaningful therapeutics to treat, prevent, or slow Alzheimer's disease, other dementias, and cognitive aging.

The Society for Women's Health Research (SWHR) is pleased to announce a travel award opportunity for neuroscience students to present their research on sex differences in the brain at a scientific conference in 2014. SWHR is accepting applications for travel awards sponsored by Donald G. and Darel Stein in memory of Anne Hammer. Awardees must provide evidence that the poster or oral presentation has been accepted for inclusion in the conference. Funds can be used to pay for expenses associated with attending a neuroscience-related conference, including an abstract submission fee, society membership and/or conference registration, and travel and/or lodging. The research presented must stem from a current project on sex differences in neuroscience.

This award program is designed to enhance our existing support of autism research by providing timely resources to enable focused experiments highly relevant to our mission. A deeper understanding of the mechanisms underlying autism spectrum disorders or potential therapeutic approaches will require investigation at multiple levels, including but not limited to studies focused on gene discovery, molecular mechanisms, circuits, anatomy, and cognition and behavior. We will consider proposals at all of these levels. The maximum budget is $60,000, including indirect costs for one (1) year, non-renewable. Explorer Awards are intended to provide resources to support exploratory experiments that will strengthen hypotheses and lead to the formulation of competitive applications for subsequent larger-scale funding by SFARI or other organizations. Innovative, high-risk/high-impact proposals are encouraged. We especially encourage applications from investigators who are new to the field of autism, but who have expertise that could be brought to bear on this complex disorder.

The Caring for Carcinoid Foundation-AACR Grant for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research represents a joint effort to promote and support innovative cancer research. This grant is available to full time, independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to carcinoid tumors or pancreatic neuroendocrine tumors. Proposed research may be in any discipline of basic, translational, clinical, or epidemiological cancer research. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to carcinoid tumor or pancreatic neuroendocrine tumor research.

The Fiscal Year 2015 Department of Defense Appropriations Act provides research funding for the following peer reviewed programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP): Alcohol and Substance Abuse Research Program - $4.0 million Amyotrophic Lateral Sclerosis Research Program - $7.5 million Autism Research Program - $6.0 million Bone Marrow Failure Research Program - $3.2 million Breast Cancer Research Program - $120.0 million Duchenne Muscular Dystrophy Research Program - $3.2 million Epilepsy Research Program - $7.5 million Gulf War Illness Research Program - $20.0 million Joint Warfighter Medical Research Program - $50.0 million Lung Cancer Research Program - $10.5 million Military Burn Research Program - $8.0 million Multiple Sclerosis Research Program - $5.0 million Neurofibromatosis Research Program - $15.0 million Neurotoxin Exposure Treatment Parkinson's Research Program - $16.0 million Orthotics and Prosthetics Outcomes - $10.0 million Ovarian Cancer Research Program - $20.0 million Peer Reviewed Alzheimer's Research Program - $12.0 million Peer Reviewed Cancer Research Program - $50.0 million Peer Reviewed Medical Research Program - $247.5 million Peer Reviewed Orthopaedic Research Program - $30.0 million Prostate Cancer Research Program - $80.0 million Spinal Cord Injury Research Program - $30.0 million Tuberous Sclerosis Complex Research Program - $6.0 million Vision Research Program - $10.0 million

This FOA relates to one of the initiatives of the SPARC (Stimulating Peripheral Activity to Relieve Conditions) Common Fund program titled: Use of Existing Market-Approved Technology for New Market Indications. By establishing effective public-private partnerships, this SPARC initiative allows supported investigators to have access to existing neuromodulation technology to explore new indications. A number of device manufacturers have entered into partnership agreements with the NIH to make their neuromodulation technology, consisting of implantable devices with recording and/or stimulation capabilities, available to SPARC's supported clinical investigators (see Device Portal for a list of companies and available technologies). The specific goal of this FOA is to promote the pre-clinical development of these technologies, in support of a new market indication, towards enabling an Investigational Device Exemption (IDE) submission for a future pilot clinical study. Awarded projects of this FOA that fully reach their pre-clinical testing milestones will be eligible for further support, subject to a subsequent FOA, to conduct a pilot clinical study. The expectation is that these pilot clinical studies will provide the initial proof-of-principle demonstrations in humans that will motivate the additional studies needed in pursuing FDA approval as a labeled indication.

This FOA relates to one of the initiatives of the SPARC (Stimulating Peripheral Activity to Relieve Conditions) Common Fund program titled: Use of Existing Market-Approved Technology for New Market Indications. By establishing effective public-private partnerships, this SPARC initiative allows supported investigators to have access to existing neuromodulation technology to explore new indications. A number of device manufacturers have entered into partnership agreements with the NIH to make their neuromodulation technology, consisting of implantable devices with recording and/or stimulation capabilities, available to SPARC's supported clinical investigators (see Device Portal for a list of companies and available technologies). The specific goal of this FOA is to promote the pre-clinical development of these technologies, in support of a new market indication, towards enabling an Investigational Device Exemption (IDE) submission for a future pilot clinical study. Awarded projects of this FOA that fully reach their pre-clinical testing milestones will be eligible for further support, subject to a subsequent FOA, to conduct a pilot clinical study. The expectation is that these pilot clinical studies will provide the initial proof-of-principle demonstrations in humans that will motivate the additional studies needed in pursuing FDA approval as a labeled indication.

The purpose of this Funding Opportunity Announcement (FOA) is to invite pre-applications from applicants who have an interest in ultimately submitting an application to "Stimulating Peripheral Activity to Relieve Conditions (SPARC): Technologies to Understand the Control of Organ Function by the Peripheral Nervous System (OT2)" (RFA-RM-16-003). The OT1 SPARC pre-application is the required first step in the application process for the companion OT2 FOA (RFA-RM-16-003). Potential applicants should read both FOAs.

The purpose of this Funding Opportunity Announcement (FOA) is to invite pre-applications from applicants who have an interest in ultimately submitting an application to "Stimulating Peripheral Activity to Relieve Conditions (SPARC): Technologies to Understand the Control of Organ Function by the Peripheral Nervous System (OT2)" (RFA-RM-16-003). The OT1 SPARC pre-application is the required first step in the application process for the companion OT2 FOA (RFA-RM-16-003). Potential applicants should read both FOAs.

PCORI seeks to fund pragmatic clinical trials, large simple trials, or large-scale observational studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving healthcare system-level approaches to managing care; communicating or disseminating research results to patients, caregivers, or clinicians; or eliminating health or healthcare disparities. Proposed studies must address critical clinical choices faced by patients, their caregivers, clinicians, or delivery systems. They must involve broadly representative patient populations and be large enough to provide precise estimates of hypothesized effectiveness differences and to support evaluation of potential differences in treatment effectiveness in patient subgroups.

This funding opportunity announcement (FOA) invites applications for mentored career enhancement (K18) awards in research areas that are highly relevant to the NIH BRAIN Initiative. This career enhancement program will support development of research capability for the BRAIN Initiative, with specific emphasis on cross-training independent investigators in a substantively different area of neuroscience, neuroethics, or in a quantitative and physical discipline (e.g., physics, chemistry, engineering, computer science, mathematics); and vice versa, cross-training independent investigators trained in a quantitative or physical discipline proposing to gain in-depth training in a high-priority area of neuroscience. The research project conducted under this K18 should enhance the candidate's ability to significantly contribute to or lead projects that investigate questions central to the goals of the BRAIN Initiative. Eligible candidates are independent investigators at any faculty rank or level.

This funding opportunity announcement (FOA) invites applications for mentored career enhancement (K18) awards in research areas that are highly relevant to the NIH BRAIN Initiative. This career enhancement program will support development of research capability for the BRAIN Initiative, with specific emphasis on cross-training independent investigators in a substantively different area of neuroscience, neuroethics, or in a quantitative and physical discipline (e.g., physics, chemistry, engineering, computer science, mathematics); and vice versa, cross-training independent investigators trained in a quantitative or physical discipline proposing to gain in-depth training in a high-priority area of neuroscience. The research project conducted under this K18 should enhance the candidate's ability to significantly contribute to or lead projects that investigate questions central to the goals of the BRAIN Initiative. Eligible candidates are independent investigators at any faculty rank or level.

These awards encourage and support scientists working on the development of novel and creative approaches to understanding brain function. The fund supports efforts to examine how a new technology may be used to monitor, manipulate, analyze, or model brain function at any level, from the molecular to the entire organism. Technology may take any form, from biochemical tools to instruments to software and mathematical approaches. Because the program seeks to advance and enlarge the range of technologies available to the neurosciences, research based primarily on existing techniques will not be considered.

These awards encourage and support scientists working on the development of novel and creative approaches to understanding brain function. The fund supports efforts to examine how a new technology may be used to monitor, manipulate, analyze, or model brain function at any level, from the molecular to the entire organism. Technology may take any form, from biochemical tools to instruments to software and mathematical approaches. Because the program seeks to advance and enlarge the range of technologies available to the neurosciences, research based primarily on existing techniques will not be considered.

The purpose of the ADI-SSS program is to provide grants to public and private entities that are operating within existing, dementia-capable, long term services and supports systems and are committed to serving populations with the most need and living with or at risk of developing Alzheimer’s disease or a related dementia and their caregivers. Successful applicants will propose services designed to address the needs of each of the three service gap areas identified in the Funding Opportunity Announcement. The grantees benefit from targeted technical assistance provided by the ACL's National Alzheimer’s and Dementia Resource Center.